Foresite Capital Management VI, LLC
Foresite Capital Management VI, LLC reported 23 holdings worth US$643M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Foresite Capital Management VI, LLC reported 23 holdings worth US$643M as of Jun 30, 2026. Largest: Cg Oncology, Inc., Alumis Inc. and Seaport Therapeutics, Inc. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 23
- Value as reported
- US$643M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Cg Oncology, Inc. | 2.37M | US$168M | 26.2% |
| Alumis Inc. | 4.25M | US$120M | 18.6% |
| Seaport Therapeutics, Inc. | 1.78M | US$38.7M | 6.0% |
| Denali Therapeutics Inc. | 1.4M | US$35.9M | 5.6% |
| Celldex Therapeutics, Inc. | 880K | US$32.7M | 5.1% |
| Agios Pharmaceuticals, Inc. | 785K | US$29.1M | 4.5% |
| Corvus Pharmaceuticals, Inc. | 1.83M | US$27.4M | 4.3% |
| Parabilis Medicines, Inc. | 999K | US$27.3M | 4.3% |
| Jade Biosciences, Inc. | 887K | US$19.7M | 3.1% |
| Hinge Health, Inc. | 220K | US$18.3M | 2.8% |
| Kymera Therapeutics, Inc. | 146K | US$16.8M | 2.6% |
| Ataibeckley Inc. | 2.75M | US$14.5M | 2.3% |
| Verastem, Inc. | 3.15M | US$12M | 1.9% |
| Beam Therapeutics Inc. | 330K | US$11.3M | 1.8% |
| Minerva Neurosciences, Inc | 1.99M | US$11M | 1.7% |
| Arrivent Biopharma, Inc. | 301K | US$10.5M | 1.6% |
| Aura Biosciences, Inc. | 1.33M | US$9.47M | 1.5% |
| Crinetics Pharmaceuticals, Inc. | 212K | US$7.93M | 1.2% |
| Research Alliance Corporation Iii | 300K | US$3.21M | 0.50% |
| Zura Bio Limited | 450K | US$2.65M | 0.41% |
| Kailera Therapeutics, Inc. | 37,500 | US$826K | 0.13% |
| Disc Medicine, Inc. | 970 | US$70,946 | 0.01% |
| Onkure Therapeutics, Inc. | 0 | US$0 | 0.00% |